Replication-competent adenoviruses (Ad's) are emerging as a promising new modality for treatment of cancer. Selective replication of viral agents in tumor may lead to improved efficacy over nonreplicating Ad's due to their inherent ability to multiply, lyse, and spread to surrounding cells. We have previously shown that an E1B 55 kDa-deleted adenovirus (YKL-1) exhibits tumor-specific replication and cell lysis, but its cytolytic effects were reduced in comparison to the wild-type adenovirus. To increase the oncolytic potency of YKL-1, we have reintroduced the Ad death protein (ADP) gene under the control of either a CMV or an MLP promoter at the E3 region of YKL-1, generating YKL-cADP and YKL-mADP Ad's, respectively. ADP is an 11.6 kDa protein encoded by the E3 transcription unit, and is required to kill adenovirus-infected cells efficiently. However, to date, the mechanism by which ADP mediates cell death has not been clearly defined. In this study, we report that ADP-overexpressing Ad markedly enhanced cytolytic effect (up to 100-fold) against all tumor cell lines tested, but did not increase cytopathic effect in normal skin fibroblast, BJ. Moreover, plaque size formed by YKL-cADP was substantially larger than that of YKL-1, indicating an enhancement in cell lysis. TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling) assay and Annexin-V/PI double staining indicate that ADP-mediated cytotoxicity was largely driven by apoptosis. Finally, YKL-cADP adenovirus also showed superior antitumor effect than YKL-1 and YKL-mADP in C33A cervical and Hep3B hepatoma xenograft tumor models. Taken together, these lines of evidence demonstrate that the newly generated adenovirus expressing ADP under the CMV promoter induces efficient but tumorselective cell lysis, which is critical for adding therapeutic value to replicating adenovirus for its use in cancer gene therapy.
A dvancement in engineering of replication-competent viruses has contributed greatly in advancing cancer gene therapy, and clinical trials with such viruses are ongoing to treat a variety of cancers. [1] [2] [3] Several geneattenuated replication-competent adenoviruses (Ad's) have been engineered for tumor selectivity, but unfortunately these gene deletions also reduce the anticancer potency of the virus. [5] [6] [7] Along this line, in our previous report, we demonstrated that E1B 55 kDa-deleted YKL-1 exhibited tumor-selective replication, but with reduced cytopathic effect (CPE) in several tumor cell lines. 4 Currently in the clinic, to ensure sufficient antitumor efficacy, attenuated replicating Ad's are being applied by multiple injections of high-titer virus or by combining with standard chemotherapy. 5, 8, 9 Unfortunately, however, significant dose escalation of the administered vector increases the risk of inducing both direct toxicity and host humoral and cellular immune responses to viral proteins and virally infected cells. 10, 11 Therefore, novel replicationselective agents with improved potency would be timely to overcome these limitations and can be applied more widely in anticancer gene therapy.
The Ad E3 transcription unit has long been considered dispensable for viral replication in vitro and until recent efforts to reduce the immune response, it has been routinely deleted from Ad vectors. The Ad E3 transcription unit encodes seven proteins (12.5K, 6.7K, gp19K, Ad death protein (ADP), RIDa, RIDb, and 14.7K) that play a prominent role in assisting viral release and evading or slowing host immune responses to a virus.
12 E3 gp19K is a membrane glycoprotein, localized in the endoplasmic reticulum (ER), which forms a complex with class I antigens and prevents their transport to the cell surface, thus preventing the killing of Ad-infected cells by CTLs. 13, 14 E3 RID (receptor internalization and degradation) complex, composed of RIDa (10.4K) and RIDb (14.5K), has been shown to block Fas-induced apoptosis of virally infected cells by downregulating the proapoptotic receptor, Fas. [15] [16] [17] Further, 10.4K/14.5K also inhibits TNF-induced cytolysis and inflammation by blocking phospholipase A2 (cPLA2)-induced release of arachidonic acid. 18, 19 The 14.7K protein seems to function more as a general inhibitor of TNF cytolysis than the 10.4K/14.5K heterodimer, which seems to be effective only in some cell types. To date, E3 6.7K and 12.5K protein functions are not clearly defined. The 6.7K is an ERlocalized integral membrane glycoprotein, whereas the 12.5K is a nonmembrane protein that is localized in the nucleus and the cytoplasm. While nearly all the other E3 genes described have immunomodulatory functions, [20] [21] [22] ADP is responsible for efficient lysis and release of viral progenies from infected cells. 23 In addition, unlike other E3 genes, ADP is expressed almost exclusively during the late phase of a viral infection. 24 In the early phase, the mRNA for ADP is relatively scarce and is only produced in low amounts. However, during the late stages, ADP is synthesized in large quantities from mRNAs derived from the major late promoter.
In an effort to improve the cytolytic capability of geneattenuated replication-competent Ad's, we have developed ADP-expressing E1B 55 kDa-deleted oncolytic Ad's. Our results demonstrate that ADP-expressing Ad's exert efficient cell lysis by enhancing viral spread and inducing apoptosis.
Materials and methods

Cell lines and cell culture
HEK293 (human embryonic kidney cell line expressing the adenoviral E1 region), liver cancer cell lines (Hep3B and SK-Hep1), lung cancer cell lines (A549 and H460), cervical cancer cell lines (C33A and HeLa), brain cancer cell line (U343), and normal skin fibroblast cell line (BJ) were purchased from American Type Culture Collection (ATCC, Manassas, VA). All cell lines except Hep3B, which was maintained in modified Eagle's medium (MEM), were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, L-glutamine (2 mM), penicillin (100 IU/ml), and streptomycin (50 mg/ml) in the presence of 5% CO 2 at 371C.
Construction of E1B-modified adenoviral vectors expressing ADP under the control of a CMV or an MLP promoter at the Ad-E3 region
To generate an Ad expressing ADP at the E3 region, we first constructed an E3 shuttle vector. The E3 left region of Ad at 26,591-28,588 bp was amplified by polymerase chain reaction (PCR) with the following primer set: 5 0 -GCCCTCGAGGCCATAGTTGCTTGCTTGCA-3 0 as the sense primer and 5 0 -GCCCAGCTGACCTGAATTA GAATAGCCCG-3 0 as the antisense primer. The primers were designed to create XhoI and PvuII sites (underlined), and the Ad total vector, pXC, 25 containing the E3 region of Ad type 5, was used as a template. The E3 right region of the Ad at 30,504-31,057 was amplified by PCR with the following primer set: 5 0 -GCCGAATTCCTGCTA GAAAGACGCAGGGC-3 0 as the sense primer and 5 0 -GCCGATATCGTCTTGCGCGCTTCATCTGC-3 0 as the antisense primer. The primers were designed to create EcoRI and EcoRV sites (underlined). The PCR product containing right or left region of E3 was digested with XhoI/PvuII and EcoRI/EcoRV, respectively, and then subcloned into the corresponding sites of pSP72, generating a pSP72-E3. The ADP region of the Ad from nucleotide 29,491-29,772 bp was amplified by PCR using primers 5
0 -GCCAAGCTTATGACCAACACAACCAA CGC-3 0 as the sense and 5 0 -CGGCTCGAGTCATACTG TAAGAGAAAAGAAC-3 0 as the antisense. The Ad total vector pXJ was used as a template for PCR amplification. The resulting 282 bp PCR product was digested with HindIII and XhoI (underlined) and ligated onto the corresponding sites of pcDNA3.1 vector, generating a pcDNA/CMV-ADP. Then, CMV-ADP-polA expression cassette was excised from the pcDNA/CMV-ADP, and subsequently cloned into the Ad E3 shuttle vector pSP72-E3 predigested with XbaI, resulting in pSP72-E3/CMV-ADP. To construct the E3 shuttle vector expressing ADP under the control of MLP, the HindIII-XhoI fragments digested from 282 bp PCR product containing the ADP gene were treated with T4 DNA polymerase, and then cloned into pSP72-E3, generating a pSP72-E3/MLP-ADP. The pSP72-E3/CMV-ADP and pSP72-E3/MLP-ADP Ad shuttle vectors were then linearized with XmnI digestion, and E1B 55 kDa-deleted oncolytic adenoviral vector pYKL-1 was linearized with SpeI digestion. The linearized adenoviral shuttle vectors were cotransformed into Escherichia coli BJ5183 together with the SpeIdigested pYKL-1 for homologous recombination. To verify the respective homologous recombinants, plasmid DNA purified from overnight E. coli culture was digested with HindIII, and the digestion pattern was analyzed. The proper homologous recombinant adenoviral plasmid DNA was digested with PacI and transfected into 293 cells to generate the ADP-expressing Ad's, YKL-cADP and YKL-mADP, which expresses ADP under the control of CMV or Ad endogenous promoter MLP, respectively (Fig 1) . The expansion, purification, titration, and quality analysis of all Ad's used were performed as described previously. 26 The titer used in this study was determined by the absorbency of the dissociated virus at A260 nm (one A260 nm unit ¼ 10 12 viral particles/ml).
Western blot analysis of ADP expression
Cell infection and lysate preparation were performed as described previously. 25 Total protein concentration was determined using the Lowry method (Bio-Rad, Hercules, CA), and 10 mg of each sample was separated by 10% reducing sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis. The gels were electroblotted onto a PVDF membrane (RPN 303F, Amersham, Arlington Heights, IL). Immunodetection was performed using the Pierce enhanced chemiluminescence system with 1 mg of primary antibodies to ADP (a kind gift from W Wold at St Louis University School of Medicine) and b-actin (sc-1615; Santa Cruz Biotech., Santa Cruz, CA). Goat anti-rabbit IgG-horseradish peroxidase (HRP) and goat anti-mouse IgG-HRP were used as secondary antibodies.
Plaque development assay
Monolayers of 293 cell line were infected with serial diluted Ads in six-well plates. After 4 hours of incubation at 371C, the infected cells were overlaid with 4 ml of 0.7% SeaPlaque agarose in DMEM with 5% fetal bovine serum. Following 7-10 days incubation, agarose overlay was removed after soaking with 10% trichloroacetic acid for 30 minutes, and the remaining cells were strained with 0.5% crystal violet in 50% methanol.
CPE assay
To evaluate the CPE, cells were plated onto 48-well plates at a density of 2-5 Â 10 4 cells/well a day prior to infection and infected with various Ad's at MOIs of 0.01-10. Their killing effect was monitored daily under a microscope. At the moment that cells infected with any one of the viruses at an MOI of 0.01-0.1 exhibited complete cell lysis, cells on the plate were stained with 0.5% crystal violet in 50% methanol.
TUNEL assay
Apoptosis was analyzed by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) assay as described previously. 25 Briefly, U343 cells were plated onto a chamber slide a day prior to infection, and infected with YKL-1, YKL-cADP, Ad-XC, or Ad-XJ at an MOI of 5. Cells treated with camptothecin (CPT) at 1 mM were used as a positive control. At 48 hours after infection by Ad or treatment with CPT, cells were then processed according to the manufacturer's instructions (ApopTag kit; Oncor, Gaithersburg, MD). The apoptotic cells were counted under magnification (Â 400) in 10 selected fields. More than 2000 cells were counted to calculate the percentages of TUNEL-positive cells (apoptotic cell ratio).
To detect apoptosis in vivo, formalin-fixed tissue sections were deparaffinized in xylene, rehydrated in graded alcohol, and transferred to PBS. The slides were treated with proteinase K (20 mg/ml) for 15 minutes, and then endogenous peroxidase was blocked using 3% hydrogen peroxide in PBS for 12 minutes. The samples were washed three times in distilled water and incubated for 10 minutes at room temperature with TdT buffer. Excess TdT buffer was drained, and the samples were incubated for 18 hours at 41C with terminal transferase and biotin-16-dUTP. The samples were then rinsed four times with TB buffer and incubated for 30 minutes at 371C with a 1:400 dilution of peroxidase-conjugated streptavidin. The slides were rinsed with PBS and incubated for 5 minutes with diaminobenzidine. The sections were then washed three times with PBS, counterstained with methylene blue, and then washed three times with PBS.
Annexin V and propidium iodide staining
Development of apoptosis and cell nuclear damage were also determined by Annexin V-FITC and propidium iodide staining, and analyzed by flow cytometry. Cells were grown on T-25 culture flasks and infected with YKL-1, YKL-cADP, Ad-XC, or Ad-XJ virus at an MOI of 5. After 3 days of infection or treatment with 1 mM CPT, both attached and floating cells were then processed according to the manufacturer's instructions in the ApoAlert Annexin V-FITC apoptosis kit (Clontech, Palo Alto, CA). Apoptosis and nuclear cell damage were quantified on a fluorescence-activated cell sorter (FACS; Becton Dickinson, Sunnyvale, CA) and data from 10,000 events were collected for further analysis.
Viral production assay
To assay for viral growth, cells were plated onto a six-well plate at about 70% confluence, and then infected with YKL-1, YKL-cADP, or YKL-mADP at an MOI of 1 and 10 in 293 and U343 cells, respectively. At various times of incubation at 371C, supernatant and cells were collected and freeze-thawed three times to release the viruses. Viral titer was then determined by performing a plaque assay on the supernatant and cell pellet samples. Figure 1 Schematic illustration of replication-competent adenoviral vectors used in this study. YKL-1 contains normal E1A and E1B 19 kDa, but lacks E1B 55 kDa; YKL-cADP and YKL-mADP comprised of the ADP gene driven by the constitutive CMV and endogenous MLP promoter inserted into the E3 region, respectively. Ad-XJ is a wild-type Ad; and Ad-XC has the same backbone as Ad-XJ genome except for the deletion of the E3 region. DE3 denotes the deletion of E3 6.7K, gp19K, ADP, 10.4K, 14.5K, and 14.7K genes. The numbers (28, 470) refer to nucleotide numbers in the Ad5 genome.
Suppression of tumor growth in vivo
Male nude mice (5-6 weeks old) were purchased from Charles River (Yokohama, Japan). Tumors were implanted onto the abdomen of each animal by subcutaneous injection of 1 Â 10 7 tumor cells (C33A cervical cancer and Hep3B hepatoma cells) in 100 ml of PBS. Tumor growth was monitored on a 2-to 3-day interval by measuring the length and width of the tumor with a caliper and calculating tumor volume on the basis of the following formula: volume ¼ 0.523LW 2 . When tumors reached a range of 60-70 mm 3 , treatment was initiated. First day of treatment was designated as day 1. Ad's were administered intratumorally (5 Â 10 8 PFU per tumor in 50 ml of PBS) on days 1, 3, and 5.
Statistical analysis
The data were expressed as mean7standard error of the mean (SEM). Statistical comparison was made using Stat View software (Abacus Concepts, Inc., Berkeley, CA) and the Mann-Whitney test (nonparametric method). The criterion for statistical significance was taken as Po.05.
Results
ADP expression kinetics controlled by the CMV and MLP promoters
To maximize the expression of ADP using a replicationcompetent Ad, we compared ADP expression levels controlled by an endogenous promoter, MLP and a strong constitutive promoter, CMV. A549 cells were first infected at an MOI of 10 with either YKL-cADP or YKL-mADP. The infected cells were then collected at 12, 24, 48, 72, and 96 hours postinfection (p.i.), and the expression kinetics of ADP was determined. For cells infected with YKL-cADP, the expression of ADP was detectable at 12 hours, reached a maximum at 24 to 48 hours, and was greatly reduced by 72 hours p.i. (Fig 2) . A possible explanation for this decline in ADP expression after 72 hours is that these infected cells began to die around 48 hours p.i. In contrast, the ADP protein expressed by the MLP promoter was detected at 48 hours and reached a strong level of expression after 72 hours. The maximum level of ADP was observed at 96 hours p.i. This observation is in good agreement with the previous finding that ADP is greatly amplified at late stages of infection.
23
CMV promoter-driven ADP-expressing Ad induced the biggest plaques
To visualize the effect of ADP expression on the cytopathic ability and viral spread into surrounding cells, plaque formation in a solid medium containing agarose was compared. Figure 3 shows a representative plaque assay with YKL-1, YKL-mADP, YKL-cADP, and a wild-type Ad Ad-XJ, which express all E3 genes including ADP. Plaques formed by YKL-cADP and Ad-XJ were substantially larger than that of YKL-1 and YKLmADP. As compared to each other, YKL-cADP developed bigger plaques (mean plaque size of 3.1870.98 mm) than Ad-XJ (mean plaque size of 2.3270.63 mm). This result indicates that the CMV promoter induced ADP expression more efficiently than the MLP promoter, leading to an early viral release and an accelerated cell-tocell viral spread.
Enhanced oncolytic effect of Ad's expressing ADP
To determine whether ADP expression could improve the oncolytic activity of a replication-competent Ad, we carried out an in vitro CPE assay. The assay is based on the idea that at low concentrations (o1 MOI/cell), viruses need to go through multiple rounds of infection, replication, viral release, and reinfection of surrounding cells in order to completely wipe out a cell monolayer. Various cancer cell lines (C33A, A549, HeLa, SK-Hep1, H460, U343) and normal skin fibroblasts (BJ) were infected with log-fold dilutions of YKL-1, YKL-mADP, YKL-cADP, Ad-XC, or Ad-XJ. Ad-XC has the same backbone as Ad-XJ genome except for the deletion of the E3 region. For the negative control, cells were infected in parallel with replication-incompetent Ad dl-CMV-Z. In cancer cells, YKL-cADP exerted marked CPE showing about 10-to 100-fold greater than that of YKL-1 (Fig 4) . Moreover, CPE of YKL-cADP was as potent as that of Ad-XJ in the C33A and HeLa cell lines. However in the BJs, ADP expression was not associated with enhancement of CPE, whereas Ad-XC or Ad-XJ led to the Replicating adenovirus overexpressing ADP C-O Yun et al destruction of the monolayers at a 100-fold higher dilution than that of the YKL-1 backbone Ad's. This result suggests that ADP expression under the control of the CMV promoter substantially improves the CPE and the viral spread ability of the oncolytic Ad in cancer cells, but its effect is significantly attenuated in normal cells.
ADP induces apoptosis
To determine whether the increased cell killing of an ADP-expressing Ad was mediated by the induction of apoptosis, internucleosomal degradation of genomic DNA, one of the important biochemical characteristics of apoptosis, was examined using a TUNEL assay. Out of the two newly engineered Ad's, YKL-cADP, was chosen to perform this study, since YKL-cADP demonstrated a substantial improvement in cytopathic effect and viral spread better than that of YKL-mADP. First, U343 human brain cancer cells were infected with oncolytic Ad's, YKL-1 and YKL-cADP, and replication-competent Ad's, Ad-XJ and Ad-XC at an MOI of 5. CPT (1 mM) was used as a positive control to induce apoptosis. At 48 hours after infection, ADP-expressing Ad's YKL-cADP and Ad-XJ induced potent apoptosis, showing that 45.21 and 36.03% of the nuclei had a nicked DNA, respectively, whereas YKL-1 and Ad-XC induced apoptosis in about 13% of the infected cells (Fig 5a and b) . The induction of apoptosis by ADP-expressing Ad's was further evaluated by FACS analysis. U343 cells were infected at an MOI of 5 with ADP-expressing Ad's (YKLcADP, Ad-XJ) and ADP-negative Ad's (YKL-1, Ad-XC). At 3 days p.i., infected cells were reacted with FITCconjugated Annexin-V and with propidium iodide to differentiate apoptotic and necrotic cells. Annexin-V detects phosphatidylserine (PS) transposition on the outer plasma membrane, which occurs in the early stage of apoptosis. 27 During later stages of cell injury the plasma membrane becomes increasingly permeable and propidium iodide enters the cell and stains chromatin, indicating cellular necrosis. In Figure 6 , the bottom left quadrant (Annexin-V À /PI À ) indicates healthy cells while the bottom right quadrant (Annexin-V þ /PI À ) represents apoptotic cells. Necrotic cells are depicted in the top quadrants (PI þ ). Of the CPT-treated cells, 65.74% of the cells were apoptotic while only 10.33% of the cells were necrotic. Cells infected with YKL-cADP showed that 23.20% were apoptotic and 41.38% were necrotic, while the YKL-1-infected cells exhibited that 7.89 and 38.72% were apoptotic and necrotic, respectively. This phenomenon of enhanced induction of apoptosis by YKL-cADP in comparison to YKL-1 was also observed for Ad-XJ versus Ad-XC. More specifically, cells infected with Ad-XJ were 22.72% apoptotic and 63.45% necrotic, while the Ad-XC-infected cells showed 3.88 and 44.81%, respectively. In general, in comparison to cells infected with ADP-negative Ad's, a greater percentage of cells was undergoing apoptosis as a result of infection by ADPexpressing Ad's.
The apoptotic potential of ADP was further investigated in a C33A xenograft model. Tumors were generated by subcutaneous injection of 1 Â 10 7 C33A cervical cancer cells into the mice abdomen, and when they reached a range of 60À70 mm 3 , PBS or 5 Â 10 8 PFU of YKL-1 or YKL-cADP was injected intratumorally. At 3 days after viral injection, apoptosis was detected using a TUNEL assay from tumor sections. As seen in Figure 7 , the apoptotic rate was significantly higher in YKL-cADPtreated tumor tissue than in PBS-or YKL-1-treated tumor tissue, thus translating in vivo.
ADP-overexpressing Ad's replicate efficiently
Premature cell lysis by induction of apoptosis may lead to early viral release, possibly resulting in the reduction of total production of viral progeny. Such a loss of viral production may reduce the efficacy of viral therapy for cancer treatment. Therefore, the effect of ADP overexpression on viral production was examined. To examine and compare viral replication of YKL-1, YKLmADP, or YKL-cADP Ad, 293 and U343 cells were infected with a specific Ad at an MOI of 1 and 10, respectively. The accumulation of viral particles in the culture medium and cell fraction was determined by performing a plaque assay on 293 cells. The growth kinetics showed that the propagation of YKL-cADP was significantly increased compared with the control vector, YKL-1, yielding about 83-fold (293 cells) and 7-fold (U343 cells) more infectious virions at 3 days after infection (Fig 8) . In contrast, total viral yield of YKLmADP was similar compared to that of YKL-1 in both 293 and U343 cells. These results indicate that the overexpression of ADP did not reduce the total number of viral progeny due to the incomplete life cycle, thus allowing for efficient viral production of YKL-cADP in both 293 (an Ad-producing cell line) and U343 (human cancer cell line) cell lines.
Enhanced antitumor effect of ADP-expressing Ad's ADP-expressing Ad's, YKL-cADP and YKL-mADP, were next examined for their ability to suppress tumor growth in human xenografts, C33A cervical cancer or Hep3B hepatoma established in nude mice. In our previous results comparing the antitumor effect of YKL-1 and wild-type Ad, wild-type Ad showed more potent antitumor effect than YKL-1 in Hep3B xenograft model. 25 However, wild-type Ad's, Ad-XC or Ad-XJ, did not induce cancer cell-selective CPE due to the presence of an intact E1B 55 kDa. Therefore, in this in vivo antitumor experiment, we compared the antitumor effect of ADP-expressing oncolytic Ad against that of YKL-1. C33A or Hep3B tumors were generated by subcutaneous injection of cells into the mice abdomen, and when they reached an average of 60-70 mm 3 , 5 Â 10 8 PFU of virus were injected intratumorally three times, every other day (Q2D Â 3). As shown in Figure 8a , viral-treated tumors were substantially delayed in their growth. More specifically C33A-bearing mice treated with PBS control reached an average tumor volume of 2591 mm 3 at day 32 post-treatment, as compared to YKL-1, YKL-cADP and YKL-mADP, which reached an average tumor volume of 132, 33, and 106 mm 3 , respectively, in the same time period. By day 60 posttreatment, YKL-1-treated tumors showed signs of regrowth but YKL-cADP-and YKL-mADP-treated tumors exhibited stasis in their growth. Tumor volume at day 60 post-treatment for these viral-treated tumors was 813, 62, and 199 mm 3 for YKL-1, YKL-cADP, and YKL-mADP, respectively. In terms of regressions, at day 60 post-treatment one out of six mice exhibited partial regression for YKL-mADP-treated tumors as compared to one out of six partial and three out of six complete regression for YKL-cADP-treated mice. The significant tumor growth suppression that was observed in the C33A xenograft was also true in the Hep3B hepatoma model (Fig 9a) . At 38-day posttreatment, control tumors reached an average tumor volume of 3641 mm , YKL-1, YKL-cADP, or PBS was injected intratumorally once (5 Â 10 8 PFU per tumor in 50 ml of PBS). At 3 days after viral injection, apoptosis was detected using a TUNEL assay from tumor sections. In YKL-cADP-treated tumor tissue, apoptotic dark brown nuclei with double-strand DNA breaks were abundant, while apoptosis was not evident in PBS-or YKL-1-treated tumor tissue. Original magnification: Â 100 and Â 400. Figure 9b shows the survival curve analysis for YKL-1-, YKL-cADP-and YKL-mADP-treated C33A or Hep3B tumor bearing mice. For C33A tumor bearing mice, 120 days after the beginning of the treatment, 80% of the animals treated with YKL-cADP were still viable, whereas only 30% of YKL-1-treated mice and 40% of YKL-mADP-treated mice were viable in the same time period. Tumor bearing mice treated with YKL-cADP survived much longer than the mice in both YKL-1-and YKL-mADP-treated groups (mean survival 100 days; Po.1). Furthermore, 6 months after treatment, 50% of YKL-cADP-treated animals were completely tumor free.
For Hep3B tumor bearing mice, it only took 38 days after the beginning of the treatment, before all control animals were killed. In comparison, even after 80 days after the beginning of the treatment, 70% of the YKLcADP-treated animals were still viable. These results demonstrate that YKL-cADP can confer significant survival benefits and tumor reduction in vivo.
Discussion
Genetically attenuated Ad's are being developed as selectively replicating anti-tumoral agents. To achieve sufficient antitumor efficacy, however, attenuated replicating Ad's are being administered by multiple injections of high-titer virus 3 or by combining with standard chemotherapy. 8, 9 This significant escalation of administered vector increases the risk of inducing both direct toxicity and host humoral and cellular immune responses.
In this study, we have explored the use of ADP to enhance the limitation of viral spread and oncolytic effect of replication-competent Ad's. ADP (also named E3 11.6 kDa protein) is an integral membrane protein encoded by the E3 transcription unit, which localizes initially to the ER and the Golgi complex, but ultimately to the nuclear membrane and Golgi at very late stages of infection (440 hours p.i.). 28, 29 Earlier studies by Tollefson et al 23 indicated that ADP may function to promote cell death. The evidence for this theory came from observations that virus mutants that lack ADP form small plaques at a slow rate. Subsequent studies established that ADP-negative mutant viruses are released from infected cells more slowly, thus taking longer for the mutant viruses to spread from cell to cell. 30 ADP is unique among the E3 proteins in that it is synthesized in small quantities during the early stages of infection, but in very large amounts from the major late transcription unit at very late stages of infection. 24 For the aim of maximizing ADP expression, we compared ADP expression levels controlled by an endogenous promoter, MLP, and a strong constitutive promoter, CMV. Western blot analysis revealed that the kinetics of ADP expression is slightly different for these two promoter systems. The CMV promoter induced high ADP expression at the early stage, while the MLP promoter-driven expression was more delayed in its onset. In a plaque formation assay, three ADP-expressing Ad's (YKL-cADP, YKL-mADP, and Ad-XJ) yielded larger plaques than an Ad that does not express this protein, YKL-1. Of the ADP-expressing Ad's, YKL-cADP developed the biggest plaques, indicating that the expression of ADP and subsequent viral release induced by the CMV promoter was more robust than either YKL-mADP or Ad-XJ. Moreover, in a CPE assay, YKL-cADP showed a greater (about 10-100 times higher) ability to lyse infected cells than either YKL-1 or YKL-mADP. This superior potency of YKL-cADP over YKL-1 or YKL-mADP was seen in all cancer cell lines examined, indicating that ADP exerts its action in a cell-type-independent manner. The enhanced potency of YKL-cADP over YKL-mADP also translated into in vivo, as greater antitumor and survival advantage was observed for YKL-cADP-treated tumor bearing mice. These lines of evidence support the conclusion that the CMV promoter is superior to the MLP promoter in inducing the expression of ADP, which subsequently then enhances viral spread and CPE of replication-competent Ad.
Previous studies and our present report demonstrate that ADP is required to kill Ad-infected cells efficiently, that is, ADP-overexpressing Ad accelerates cell-to-cell viral spread, and this enhanced vector spread results in improved oncolytic properties of the vector. [30] [31] [32] [33] [34] Ramachandra et al have reported that ADP-overexpressing replication-competent Ad's displayed increased CPE in cell culture compared to the wild-type Ad5 and improved the survival time of mice bearing intraperitoneal tumors compared to vectors that do not overexpress ADP. 34 Other investigators have also shown that the ADPoverexpressing replication-competent Ad's were more efficacious in retarding the growth of human tumor xenografts in nude mice than the cognate virus expressing wild-type levels of ADP. 31, 32 However, to date, the exact mechanism by which ADP exerts its effect has not been clearly defined. To elucidate the underlying mechanism responsible for rapid cell lysis of YKL-cADP Ad, Annexin-V/PI double staining and TUNEL assay detecting apoptosis were employed. In the TUNEL assay, Ad's expressing ADP, YKL-cADP, and Ad-XJ induced potent apoptosis in a higher percentage of infected cells in comparison to ADP-negative counterpart Ad's, YKL-1 and Ad-XC, respectively. Following Annexin-V/PI double staining, a higher fraction of apoptotic cells were generated when cells were infected with YKL-cADP or Ad-XJ in comparison to the cells infected with ADP-negative Ad's, YKL-1 or Ad-XC. To further ascertain that Ad expressing ADP exerts its antitumor effect through ADP-mediated apoptosis, tumor tissue was evaluated for the induction of apoptosis. In these tissue sections, the rate of apoptosis was significantly higher in YKL-cADP than in PBS-or YKL-1-treated tumors. These lines of evidence provide strong support that ADP exerts its action by inducing apoptosis. Cancer gene therapy with a replicating Ad expressing ADP offers unique advantages over current approaches. First, the introduction of ADP endows early viral release and marked improvement in CPE in a variety of cancer cells. Second, the induction of apoptosis by ADP expression may allow for overcoming resistance to cancer therapies caused by the inactivation of apoptotic pathways, which occurs in the majority of tumors. In sum, the marked antitumoral effect and survival benefits of YKL-cADP as we have shown in this report may allow for lower vector dose administration with fewer unwanted side effects. 
